Anti-RUNX1/RUNX2/RUNX3 Polyclonal Antibody (HX866014) is a rabbit polyclonal antibody detecting RUNX1 in ELISA, IHC, WB. Suitable for Human, Mouse, and Rat.
Highlights
●Affinity Purified — Minimal background and high purity for reliable results.
●Multi-Application — Validated across multiple applications.
●Multi-Species — Cross-reactive for translational research.
Species reactivity
Human, Mouse, Rat
Applications
ELISA, IHC, WB
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant human RUNX1 (Asp6-Tyr453).
Target
Isoform AML-1G of Runt-related transcription factor 1, Acute myeloid leukemia 1 protein, Core-binding factor subunit alpha-2, CBF-alpha-2, Oncogene AML-1, Polyomavirus enhancer-binding protein 2 alpha B subunit, PEA2-alpha B, PEBP2-alpha B, SL3-3 enhancer factor 1 alpha B subunit, SL3/AKV core-binding factor alpha B subunit, RUNX1, AML1, CBFA2
Please refer to the specific buffer information in the hardcopy of datasheet or the lot-specific COA.
Product Usage Information
Application
Dilution
ELISA
1:5000-1:20000
IHC
1:50-1:500
WB
1:500-1:2000
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Background
Runt-related transcription factor 1 is a ~48 kDa protein. Forms the heterodimeric complex core-binding factor (CBF) with CBFB. RUNX members modulate the transcription of their target genes through recognizing the core consensus binding sequence 5'-TGTGGT-3', or very rarely, 5'-TGCGGT-3', within their regulatory regions via their runt domain, while CBFB is a non-DNA-binding regulatory subunit that allosterically enhances the sequence-specific DNA-binding capacity of RUNX. The heterodimers bind to the core site of a number of enhancers and promoters, including murine leukemia virus, polyomavirus enhancer, T-cell receptor enhancers, LCK, IL3 and GM-CSF promoters (Probable). Essential for the development of normal hematopoiesis. Acts synergistically with ELF4 to transactivate the IL-3 promoter and with ELF2 to transactivate the BLK promoter.
1. Fujimoto, T. et al. (2007) The EMBO journal 26, 2361-70. PMID: 17431401
2. Mao, S. et al. (1999) Molecular and cellular biology 19, 3635-44. PMID: 10207087
3. Cho, JY. et al. (2004) The Journal of biological chemistry 279, 19512-22. PMID: 14970218
4. Ono, M. et al. (2007) Nature 446, 685-9. PMID: 17377532
中文
English
한국어
日本語
Español
Français
Русский
